Litigation and opioid-related expenses in the three months ended December 31, 2021 included a $6.8 million accrual related to opioid litigation settlements and $25.8 million of legal fees in connection with opioid lawsuits and investigations.Acquisition, integration, and restructuring expenses in the three months ended December 31, 2022 included $21.0 million of acquisition-related deal and integration costs primarily related to the integration of Alliance Healthcare, $12.9 million related to our business transformation efforts, and $3.3 million of other restructuring initiatives and severance.Acquisition, integration, and restructuring expenses in the three months ended December 31, 2021 included $21.4 million of acquisition-related deal and integration costs primarily related to the integration of Alliance Healthcare, $6.6 million of other restructuring initiatives and severance, and $4.3 million related to our business transformation efforts.Income Tax Expense Our effective tax rates were 19.8% and 24.6% for the three months ended December 31, 2022 and 2021, respectively.Cash FlowsAs of December 31, 2022 and September 30, 2022, our cash and cash equivalents held by foreign subsidiaries were $830.6 million and $688.4 million, respectively.The largest amount of intra-period borrowings under our revolving and securitization credit facilities that was outstanding at any one time during the three months ended December 31, 2022 and 2021 was $1,315.0 million and $266.4 million, respectively.We had $1,558.1 million and $710.8 million of cumulative intra-period borrowings that were repaid under our credit facilities during the three months ended December 31, 2022 and 2021, respectively.Capital expenditures in the three months ended December 31, 2022 and 2021 were $75.7 million and $79.7 million, respectively.Our liability for uncertain tax positions was $553.5 million (including interest and penalties) as of December 31, 2022.The effective tax rate for the three months ended December 31, 2022 was lower than the U. S. statutory rate primarily due to the benefit of non-U. S. income taxed at rates lower than the U. S. statutory rate, as well as tax benefits associated with the vesting of restricted stock units and stock option exercises, offset in part by U. S. state income taxes.The effective tax rate for the three months ended December 31, 2022 was lower than the U. S. statutory rate primarily due to the benefit of non-U. S. income taxed at rates lower than the U. S. statutory rate, as well as tax benefits associated with the vesting of restricted stock units and stock option exercises, offset in part by U. S. state income taxes.The effective tax rate in the three months ended December 31, 2021 was higher than the U. S. statutory rate primarily due to U. S. state income taxes as well as discrete tax expense associated with foreign valuation allowance adjustments.